Immunomedicine
Biotechnology company developing platform-based immunotherapeutic drugs for cancer and drug‑resistant infectious diseases. Uses a viral‑derived vector delivery system to activate intracellular innate immunity (RIG-I) and combines gene, nucleic acid and cell therapy approaches. Operates university‑affiliated laboratory facilities and pursues academic and industry collaborations, pre‑IND regulatory engagement, and global commercialization planning.
Industries
Nr. of Employees
small (1-50)
Immunomedicine
Patents
Methods for the production of hemagglutinating virus of Japan and adenovirus using cultured cells
US-8012749-B2
View Details
Methods for the production of hemagglutinating virus of Japan and adenovirus using cultured cells
US-8012749-B2
View DetailsProducts
Vector-based nucleic acid delivery platform
A viral‑derived vector delivery platform designed to carry nucleic acid payloads and activate intracellular innate immune pathways to enhance cellular immunity for therapeutic applications.
Plasmid DNA therapeutic constructs
Plasmid DNA constructs under development, including examples encoding human CXCL2 and antigen + immune activator combinations (e.g., HSP65 + IL‑12), intended to recruit immune cells and activate cellular immunity.
HVJ-E粒子・単鎖RNA核酸医薬
HVJ-E粒子の中に断片化した単鎖RNAを内包した核酸医薬で、がん細胞死の誘導や多彩な免疫細胞の活性化作用を持ちます。
RNA and other nucleic acid drugs
Single-stranded RNA fragment in HVJ-E particles that induces cancer cell death and release/recognition of cancer antigens, activating various immune cells.
HVJ-E
Core technology and immunotherapy platform that targets RIG-I as an immunostimulant to develop advanced medicines for cancer and other difficult-to-treat diseases by combining gene nucleic acids, cells, and pharmaceuticals.
HVJ-E技術
大阪大学が発明した遺伝子核酸医薬用のベクター（ドラッグデリバリーシステム）であり、RIG-I受容体を活性化して体全体の免疫力を増強する最先端治療技術プラットフォーム。
Vector-based nucleic acid delivery platform
A viral‑derived vector delivery platform designed to carry nucleic acid payloads and activate intracellular innate immune pathways to enhance cellular immunity for therapeutic applications.
Plasmid DNA therapeutic constructs
Plasmid DNA constructs under development, including examples encoding human CXCL2 and antigen + immune activator combinations (e.g., HSP65 + IL‑12), intended to recruit immune cells and activate cellular immunity.
HVJ-E粒子・単鎖RNA核酸医薬
HVJ-E粒子の中に断片化した単鎖RNAを内包した核酸医薬で、がん細胞死の誘導や多彩な免疫細胞の活性化作用を持ちます。
RNA and other nucleic acid drugs
Single-stranded RNA fragment in HVJ-E particles that induces cancer cell death and release/recognition of cancer antigens, activating various immune cells.
HVJ-E
Core technology and immunotherapy platform that targets RIG-I as an immunostimulant to develop advanced medicines for cancer and other difficult-to-treat diseases by combining gene nucleic acids, cells, and pharmaceuticals.
HVJ-E技術
大阪大学が発明した遺伝子核酸医薬用のベクター（ドラッグデリバリーシステム）であり、RIG-I受容体を活性化して体全体の免疫力を増強する最先端治療技術プラットフォーム。
Services
Joint research partnerships with academic and industry organizations to co‑develop immunotherapeutic candidates and share R&D resources.
Joint research partnerships with academic and industry organizations to co‑develop immunotherapeutic candidates and share R&D resources.
Expertise Areas
- Immunotherapy platform development
- Nucleic acid therapeutics (mRNA, siRNA, plasmid DNA)
- Vector-mediated drug delivery
- Immuno-oncology preclinical research
Key Technologies
- Vector-mediated nucleic acid delivery
- Plasmid DNA engineering
- mRNA and siRNA therapeutics
- Innate immune receptor (RIG-I) activation
News & Updates
Announcement of the launch of the company's English website on November 8, 2024.
Won the Grand Prize and sponsor awards at The JSSA KANSAI Pitch Award hosted by the Japan Startup Support Association.
Secured funding through a J‑KISS financing instrument.
Won the Grand Prize at The JSSA Tokyo Pitch Award & Power Matching Booth Vol.58 hosted by the Japan Startup Support Association.
Announcement of the launch of the company's English website on November 8, 2024.
Won the Grand Prize and sponsor awards at The JSSA KANSAI Pitch Award hosted by the Japan Startup Support Association.
Secured funding through a J‑KISS financing instrument.
Won the Grand Prize at The JSSA Tokyo Pitch Award & Power Matching Booth Vol.58 hosted by the Japan Startup Support Association.